Stay nerdy, my friends!

Arati Korwar
Arati Korwar|February 24, 2012

Last week, a JMP user posted a funny comment on LinkedIn about JMP. It was a takeoff on the amusing Dos Equis commercials about the Most Interesting Man in the World. According to the ads, the Most Interesting Man has lived a life so remarkable that, for instance, “he can [...]

Post a Comment

JMP Genomics shows the future of biomarker discovery

Bernard McKeown
Bernard McKeown|February 22, 2012

The Biomarkers Congress is Europe’s largest biomarkers event showcasing case studies in biomarker discovery, and validation strategies and regulation. Its industry delegate list reads like a who’s who in the world of biomarkers, with representation from throughout the globe, for example, AstraZeneca, GSK, Merck, Roche and Takeda. It was fantastic [...]

Post a Comment

JMP Clinical present at PhUSE, Brighton 2011

Valerie Nedbal
Valerie Nedbal|December 7, 2011

The Pharmaceutical Users Software Exchange (PhUSE) conference in the British seaside resort of Brighton was nearly two months ago, but I am still thinking about it; PhUSE provided an opportunity to learn from experts and share ideas about the application of software in the pharmaceutical industry. The theme for this [...]

Post a Comment

Accounting for the time at which an adverse event occurs

Richard Zink
Richard Zink|December 6, 2011

In a previous post, I described how JMP Clinical allows you to specify time windows within an incidence analysis. Specifying time windows can provide a more informative analysis since it is possible to view how the risk of adverse events (AEs) changes over the course of a clinical trial. However, the [...]

Post a Comment

Discovering unreported adverse events using your findings data

Richard Zink
Richard Zink|October 25, 2011

When designing case report forms (CRFs) for a clinical trial, it is important to minimize or eliminate redundancies in the collected information. Such redundancies can lead to inconsistencies that require a query to the clinical site for resolution. In a poorly designed CRF, data conflicts can be so numerous that [...]

Post a Comment

Summarizing the incidence of adverse events

Richard Zink
Richard Zink|October 11, 2011

The analysis of adverse events (AEs) suffers from the problem of dimensionality. It is impossible to predict what AEs will occur on study, and there are often numerous events by study’s end. Typically, the incidence of adverse events is summarized in tables, with events coded by a medical dictionary, such [...]

Post a Comment

JMP Clinical 3.1 generates adverse event narratives

Richard Zink
Richard Zink|October 5, 2011

In a clinical trial, when a subject has a serious adverse event (SAE) or other significant adverse event (AE), such as those leading to the discontinuation of the study, a narrative is written for the clinical study report. These narratives summarize the details surrounding the event to enable understanding of [...]

Post a Comment